Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Murielle Roussel

18PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsNgā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

Sort by Publication Date:
|Jun 08, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

|Sep 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

Anaïs Schavgoulidze, Aurore Perrot, Xavier Leleu

|Feb 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Aurore Perrot, Thierry Facon, Torben Plesner

|Jan 22, 2025
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.

Aurore Perrot, Cyrille Touzeau, Jerome Lambert

|Sep 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).

Olivier Tournilhac, Bettina Altmann, Birte Friedrichs

|May 09, 2024
Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.

Murielle Roussel, Nathalie Texier, Virginie Nael

Pageof 3

Frequent Collaborators

7 joint publications

Aurore Perrot

5 joint publications

Jill Corre

3 joint publications

Xavier Leleu

3 joint publications

Salomon Manier

3 joint publications

Jean-Marc Schiano de Colella

2 joint publications

Guillaume Cartron

2 joint publications

Gandhi Damaj

2 joint publications

David Sibon

2 joint publications

Lotfi Benboubker

2 joint publications

Olivier Tournilhac

Frequent Collaborators

7 joint publications

Aurore Perrot

5 joint publications

Jill Corre

3 joint publications

Xavier Leleu

3 joint publications

Salomon Manier

Predictive and prognostic markers